Want to see GB:IBAI full AI Analyst Report?
IBAI Stock Chart & Stats
0.60 p
0.00 p(0.00%)
At close: 4:00 PM EDT
0.60 p
0.00 p(0.00%)
Day’s Range― - ―
52-Week Range0.40 p - 1.40 p
Previous CloseN/A
Volume362.14K
Average Volume (3M)1.79M
Market Cap
£1.85M
Enterprise Value2.04 p
Total Cash (Recent Filing)£49.38K
Total Debt (Recent Filing)£177.45K
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Apr 29, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding246,709,800
10 Day Avg. Volume1,015,341
30 Day Avg. Volume1,785,648
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)8.72
Price to Sales (P/S)2.60
P/FCF Ratio27.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginAn ~82% gross margin indicates structurally favorable unit economics and strong product/service pricing power. High gross margins create durable operating leverage as revenue grows, enabling the company to scale contribution profitably and fund R&D or commercial expansion without proportional increases in cost of goods sold.
Steady Revenue GrowthConsistent top-line growth over multiple years signals ongoing market traction and incremental adoption of the company’s AI-driven healthcare offerings. Durable revenue expansion supports operating leverage, provides a base for margin improvement, and validates demand beyond short-term cyclical moves.
Positive Operating And Free Cash Flow In 2025A switch to positive operating and free cash flow is a structurally important inflection: it reduces near-term reliance on external funding and demonstrates underlying cash-generating capacity. If sustained, this improves runway and allows reinvestment into product development or sales to support longer-term growth.
Bears Say
Large Ongoing Net LossesA net loss equal to roughly half of revenue is a substantial structural headwind: it erodes retained earnings, limits the ability to self-fund growth, and means management must close a large profitability gap. Persisting losses raise the risk of dilution or constrained investment if margins don’t improve.
Eroded Equity And Rising LeverageA materially reduced equity base and a step-up in leverage weaken financial flexibility and increase refinancing risk. With limited capital buffer, adverse results or slower cash recovery could force dilutive raises or restrictive covenant outcomes, constraining strategic options and capital allocation over the medium term.
Volatile Cash Flow HistoryWhile 2025 shows positive free cash flow, the underlying volatility and prior multi-year cash burn indicate the improvement may not be durable without operational consistency. Intermittent cash swings heighten the need for contingency financing and make long-term planning and investment riskier for stakeholders.
IQ-AI News
IBAI FAQ
What was IQ-AI Limited’s price range in the past 12 months?
IQ-AI Limited lowest share price was 0.40 p and its highest was 1.40 p in the past 12 months.
What is IQ-AI Limited’s market cap?
IQ-AI Limited’s market cap is £1.85M.
When is IQ-AI Limited’s upcoming earnings report date?
IQ-AI Limited’s upcoming earnings report date is Apr 29, 2027 which is in 262 days.
How were IQ-AI Limited’s earnings last quarter?
IQ-AI Limited released its earnings results on Jul 29, 2026. The company reported 0 p earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is IQ-AI Limited overvalued?
According to Wall Street analysts IQ-AI Limited’s price is currently Overvalued.
Does IQ-AI Limited pay dividends?
IQ-AI Limited pays a Semiannually dividend of 0.8 p which represents an annual dividend yield of N/A. See more information on IQ-AI Limited dividends here
What is IQ-AI Limited’s EPS estimate?
IQ-AI Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IQ-AI Limited have?
IQ-AI Limited has 246,709,800 shares outstanding.
What happened to IQ-AI Limited’s price movement after its last earnings report?
IQ-AI Limited reported an EPS of 0 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of IQ-AI Limited?
Currently, no hedge funds are holding shares in GB:IBAI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IQ-AI Limited
Imaging Biometrics Ltd., founded in 1965 and headquartered in Saint Helier, Jersey, specializes in medical imaging diagnostics and clinical patient care. The company extends its services across the United Kingdom, Switzerland, the European Union, and the United States. Its operations are structured into three main segments: a Holding Company, Medical Software, and Oral Gallium Maltolate (GaM). The Medical Software division develops a comprehensive suite of ready-to-use software applications for the healthcare sector. This portfolio includes IB Clinic, which serves as the foundational platform for all IB software; IB Neuro, a specialized platform for MR DSC perfusion processing; and IB Delta Suite, designed to generate Delta T1 maps from routine MR examinations. Further offerings comprise IB DCE and IB Diffusion, both providing in-depth insights into blood flow and water diffusion throughout the body. For non-invasive assessments, the company provides StoneChecker and Liver Surface Nodularity, which are computed tomography (CT) processing tools that assist clinicians in evaluating kidney stones and liver health. Additional software includes IB ASL, used to measure cerebral blood flow for diagnosing conditions like stroke and dementia, and IB Zero G, an innovative technology that eliminates the need for gadolinium contrast agents in standard imaging. The suite also features IB Nimble, facilitating virtual collaboration among healthcare professionals. Beyond software, the company's Oral Gallium Maltolate (GaM) segment is actively pursuing the development of IB003, a gallium maltolate drug candidate currently in Phase 1 clinical trials for treating glioblastoma. Imaging Biometrics Ltd. also offers consulting services. The entity, which was previously known as IQ-AI Limited, is slated to adopt the name Imaging Biometrics Ltd. in May 2025.
Technical Analysis
Cambridge Cognition Holdings
―
Genedrive
―
IXICO plc
―
Oxford BioDynamics
―
Renalytix
―